Quality of life is impaired in myelin oligodendrocyte glycoprotein antibody associated disease.

ABSTRACT:

Background

There is a paucity of studies examining quality of life (QoL) in people with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

Methods

A cross-sectional, online, self-administered survey was distributed. Data elements included demographic and clinical characteristics, and QoL in Neurological Disorders (Neuro-QoL) short form questionnaires. Neuro-QoL domain scores were compared to reference populations, yielding standardized T-scores. Symptom severity was categorized as mild, moderate, or severe, using standard Neuro-QoL cut points.

Results

A total of 259 participants completed the survey. Neuro-QoL domain impairment was present in a significant proportion of respondents (anxiety: 58.1%, depression: 30.7%, stigma 29.8%, cognition: 58.5

SUBMITTER: Said Y 

PROVIDER: S-EPMC11342330 | biostudies-literature | 2024 Jul-Sep

REPOSITORIES: biostudies-literature